Columbia Laboratories (CBRX)
Columbia Laboratories Earnings Yield: 31.81%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBRX Earnings Yield Rankings
| Overall | 97th percentile | 102 of 4312 |
| Sector | 97th percentile | 10 of 492 in Healthcare |
| Industry | 90th percentile | 1 of 11 in Drug Delivery & Accessories |
CBRX Earnings Yield Range, Past 5 Years
| Minimum | -45.79% | Mar 2010 |
| Maximum | 31.81% | May 25 2012 |
| Average | -12.43% |
About Earnings Yield
Earnings yield is earnings per share from the previous four quarters divided by the share price. It is the reciprocal of the P/E ratio. The earnings yield is quoted as a percentage, which illustrates the percentage of each dollar invested that was earned by the company during the past twelve months.
The earnings yield can be used to compare the earnings of a stock, sector or the whole market against bond yields. Generally, the earnings yields of equities are higher than the yield of risk-free treasury bonds. Financial theorists argue that this difference exists because stock earnings are riskier than bond coupon payments.
If a company has an earnings yield of 64%, investors are purchasing $0.64 of earnings per dollar invested.
Learn More
You may also be interested in these CBRX related companies
CBRX News
Listen to $CBRX Q1 2012 earnings call - live at 11:00 AM, ondemand after - http://stks.co/3ftI
about 24 days ago by earningscast
about 24 days ago by earningscast
@peterumble I first heard of $ALXA and $CBRX from you. Bought in back in March. Not happy...
about 24 days ago by Flynt2012
about 24 days ago by Flynt2012
$CBRX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3WzM
about 32 days ago by MarketBrief
about 32 days ago by MarketBrief
Columbia Laboratories to Discuss First Quarter 2012 Financial Results on May 4 Conference Call
Apr 24, 4:31PM Business Wire
Apr 24, 4:31PM Business Wire
Pomerantz Law Firm Reminds Shareholders of Columbia Laboratories, Inc. of Upcoming Deadline -- CBRX
Mar 23, 1:39PM GlobeNewswire
Mar 23, 1:39PM GlobeNewswire
$CBRX any idea of when they go in front of FDA again for progesterone gel?
about 66 days ago by investingfelon
about 66 days ago by investingfelon
$CBRX Looks like it has a potential upside. I'm in .71 http://stks.co/2zuV
about 68 days ago by Flynt2012
about 68 days ago by Flynt2012
Pomerantz Law Firm Reminds Shareholders of Columbia Laboratories, Inc. of Upcoming Deadline -- CBRX
Mar 16, 10:18AM GlobeNewswire
Mar 16, 10:18AM GlobeNewswire
$CBRX has reportedly hired Cowen to help it explore potential strategic transactions.
about 76 days ago by MilionCapital
about 76 days ago by MilionCapital
Columbia Labs (CBRX) Retains Advisor in Evaluating Strategic Alternatives
Mar 13, 6:53AM Street Insider
Mar 13, 6:53AM Street Insider
$CBRX Columbia Laboratories Hires Cowen and Company to Assist in Evaluating Potential Strategic Transactions
about 76 days ago by biotech
about 76 days ago by biotech
Although not THAT invested, im holdin about 200 shares. $cbrx .Cant remember what i saw in that turd. Have wait it out and go down with ship
about 80 days ago by Woodeks
about 80 days ago by Woodeks
A 3.50 stock worth .66 cents! $cbrx ! Im holding some if that turd too.
about 80 days ago by Woodeks
about 80 days ago by Woodeks
Pomerantz Law Firm Reminds Shareholders of Columbia Laboratories, Inc. of Upcoming Deadline -- CBRX
Mar 09, 4:13PM GlobeNewswire
Mar 09, 4:13PM GlobeNewswire
Listen to $CBRX Q4 2011 earnings call - live at 10:00 AM, ondemand after - http://stks.co/2jXU
about 81 days ago by earningscast
about 81 days ago by earningscast
Columbia Laboratories, Inc. (CBRX) Narrows Q4 Loss by 5c/Share; Revs Lighten
Mar 08, 6:57AM Street Insider
Mar 08, 6:57AM Street Insider
Columbia Laboratories Reports Fourth Quarter and Year-End 2011 Financial Results
Mar 08, 6:55AM Business Wire
Mar 08, 6:55AM Business Wire
Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter
Mar 06, 4:45PM Business Wire
Mar 06, 4:45PM Business Wire
Columbia Laboratories Will Present March 5th at Cowen and Company Health Care Conference
Feb 29, 6:55AM Business Wire
Feb 29, 6:55AM Business Wire
$CBRX i just dodged a bullet on this. Im curious to kno how to win FDA approval after a month of rejection. What kind if improvement is it
about 91 days ago by Kwame123
about 91 days ago by Kwame123
$CBRX Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
about 91 days ago by biotech
about 91 days ago by biotech
$CBRX fda approval? They have to announce something either way... must be waiting for tomorrow morning.
about 91 days ago by anthony73
about 91 days ago by anthony73
Pomerantz Law Firm Reminds Shareholders of Columbia Laboratories, Inc. of Upcoming Deadline -- CBRX
Feb 24, 5:12PM GlobeNewswire
Feb 24, 5:12PM GlobeNewswire
Faruqi & Faruqi, LLP Announces Investigation of Columbia Laboratories Inc.
Feb 09, 11:00AM PR Newswire
Feb 09, 11:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBRX | 0.6602 | +0.02 | +3.27% | 57.66M |
| CBRL | 59.82 | +0.35 | +0.59% | 1.375B |
| CBPO | 7.90 | -0.03 | -0.38% | 202.24M |
| CBP | 0.56 | +0.01 | +1.82% | 20.85M |
| CBOU | 11.61 | +0.25 | +2.20% | 243.23M |
| CBOE | 25.24 | -0.15 | -0.59% | 2.241B |
| CBNJ | 8.19 | -0.03 | -0.36% | 109.01M |
| CBMX | 0.92 | -0.04 | -4.17% | 9.844M |
| CBM | 7.08 | +0.00 | +0.00% | 209.71M |
| BRS | 43.38 | -0.33 | -0.76% | 1.548B |
